## CONTENTS

1. INTRODUCTION
   1.1 Overview of cancer 1
   1.2 Cancer prevalence, causes and risk factors 3
   1.3 Cancer treatment 5
   1.4 Cancer chemotherapy and its evolution 8
   1.5 Barriers encountered in cancer chemotherapy 11
   1.6 Side effects associated with chemotherapy 12
   1.7 Engineering aspects of cancer chemotherapy 14
      1.7.1 Polymeric delivery of chemotherapeutics 14
      1.7.2 Polymers used for drug delivery applications 15
   1.8 Prodrugs 16
      1.8.1 The concept of prodrug 16
      1.8.2 Ringsdorf model for design of polymeric prodrugs 18
      1.8.3 Polymer-drug conjugates 19
   1.9 Drug delivery 21
   1.10 Lysosomotropic delivery of polymer-drug conjugates 23
   1.11 The origin and the properties of Elastin like polypeptides (ELPs) 24
   1.12 Drug delivery applications of ELPs 28
   1.13 Doxorubicin 28
   1.14 Literature review on drug delivery applications of ELPs 33

2. SCOPE AND OBJECTIVES 42

3. EXPERIMENTAL 47
   3.1 Materials 47
   3.2 Synthesis of the thermally responsive ELP-Doxorubicin conjugate 47
      3.2.1 Solid phase peptide synthesis of the short ELP 47
      3.2.2 Preparation of succinic anhydride derivative of ELP 48
      3.2.3 Preparation of hydrazide derivative of ELP 49
      3.2.4 Preparation of ELP-Doxorubicin conjugate 49
3.3 Purification of the ELP
3.4 Lyophilization of the ELP
3.5 Characterization of the ELP and the ELP-Doxorubicin conjugate
   3.5.1 FTIR
   3.5.2 ESI-MS
   3.5.3 1D and 2D NMR studies
3.6 Turbidimetry
3.7 Differential scanning calorimetry
3.8 Circular dichroism spectroscopy
3.9 Cell and cell culture
3.10 In vitro cytotoxicity studies
3.11 Flow cytometry
3.12 Confocal fluorescence microscopy

4. RESULTS AND DISCUSSION
4.1 Synthesis of the thermally responsive ELP-Doxorubicin conjugate
4.2 Purification of the crude ELP
4.3 ESI-MS characterization of the ELP and the ELP-Doxorubicin conjugate
4.4 FTIR
   4.4.1 FTIR spectrum of Doxorubicin
   4.4.2 FTIR spectrum of the ELP
   4.4.3 FTIR spectrum of the ELP-Doxorubicin conjugate
4.5 H¹NMR
   4.5.1 H¹NMR of Doxorubicin
   4.5.2 H¹NMR of the ELP
   4.5.3 H¹NMR of the ELP-Doxorubicin conjugate
4.6 C¹³NMR
   4.6.1 C¹³NMR of Doxorubicin
   4.6.2 C¹³NMR of the ELP
   4.6.3 C¹³NMR of the ELP-Doxorubicin conjugate
4.7 Two dimensional COSY NMR
   4.7.1 Two dimensional COSY NMR of the ELP  72
   4.7.2 Two dimensional COSY NMR of the ELP-Doxorubicin conjugate  73
4.8 Two dimensional HSQC NMR
   4.8.1 Two dimensional HSQC NMR of the ELP  74
   4.8.2 Two dimensional HSQC NMR of the ELP-Doxorubicin conjugate  75
4.9 Two dimensional TOCSY NMR
   4.9.1 Two dimensional TOCSY NMR of the ELP  77
   4.9.2 Two dimensional TOCSY NMR of the ELP-Doxorubicin conjugate  78
4.10 Turbidimetry  79
4.11 Differential scanning calorimetry  80
4.12 Circular dichorism spectroscopy  81
4.13 In vitro cytotoxicity studies  82
4.14 Flow cytometry  83
4.15 Confocal fluorescence microscopy  85
4.16 Discussion  86
5. SUMMARY AND CONCLUSIONS  94
6. BIBLIOGRAPHY  100
7. ANNEXURES  114